Sunstone
  • Home
  • What We Do
  • Investment Strategy
  • Funds
  • People
  • Business Development Advisory Board
  • Portfolio
  • News & Insights
  • Download Area
  • Contact
Select Page

Galecto Announces First Patient Treated in Phase 2a Trial of the Oral LOXL2 Inhibitor GB2064 in Myelofibrosis (the MYLOX-1 Trial)

19/08/2021

Galecto Announces First Patient Treated in Phase 2a Trial of the Oral LOXL2 Inhibitor GB2064 in Myelofibrosis (the MYLOX-1 Trial) Galecto, Inc. (NASDAQ: GLTO), a biotechnology company focused on the development of novel treatments for fibrosis and cancer, today...

Recent Posts

  • Neumirna Therapeutics secures euro 20M in Series A financing
  • Are Series A radically growing?
  • Saving Lives with Venture Capital
  • The VC summer dream – the Fund Returner
  • Ascelia Pharma Successfully Meets Primary Endpoint with Strong Headline Results in Orviglance Phase 3 Study

Recent Comments

    Archives

    • January 2025
    • October 2024
    • September 2024
    • July 2024
    • May 2024
    • March 2024
    • February 2024
    • December 2023
    • November 2023
    • October 2023
    • August 2023
    • July 2023
    • April 2023
    • March 2023
    • February 2023
    • January 2023
    • December 2022
    • October 2022
    • September 2022
    • June 2022
    • March 2022
    • February 2022
    • January 2022
    • November 2021
    • October 2021
    • September 2021
    • August 2021
    • May 2021
    • April 2021
    • March 2021
    • February 2021
    • January 2021
    • December 2020
    • November 2020
    • October 2020
    • September 2020
    • August 2020
    • July 2020
    • June 2020
    • May 2020
    • April 2020
    • September 2019
    • July 2019
    • May 2019
    • March 2019
    • February 2019

    Categories

    • Ikke-kategoriseret
    • Insights
    • News

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    Supported by:

    Member of:

    Cookie Policy
    Privacy Policy
    CSR Policy
    Tax Policy

    Supported by:

    Member of:

    Cookie Policy
    Privacy Policy
    CSR Policy
    Tax Policy

    Sustainability-related disclosures    ·     No consideration of sustainability adverse impacts
    Design TR-Media ApS ©2021

    We use cookies on the website sunstone.eu in order to generate statistics and to maximize user-friendliness and improve functionality. By using our website, you consent to our use of cookies. Click on cookie settings below if you wish to disable cookies. Or you can read more about what cookies are, how we use them and how you disable cookies Here.
    Cookie settingsAccept
    Privacy & Cookies Policy

    Privacy Overview

    This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
    Necessary
    Always Enabled
    Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
    Non-necessary
    Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
    SAVE & ACCEPT